Resum
Studies that associated oestrogen-progestogen oral contraceptive (OC) use with altered glucose and lipid metabolisms in women did not account for possible influence in dietary magnesium. The use of OC and glucose and lipid metabolism seems to remain a broad public health concern since over 100 million women use OC world wide for a prolonged period of time. The study, therefore, sought to investigate in a female rat model whether or not glucose intolerance and dyslipidaemia associated with OC are influenced by dietary magnesium status. Control and OC-treated rats were maintained on control diet, whereas OC+ Mg- treated rats were on high magnesium diet. OC- treated and OCMg treated rats also received a combination of OC steroids, ethinyl oestradiol and norgestrel (orally). When compared with the controls, OC treatment led to significant reduced glucose tolerance and plasma HDL-cholesterol and significant increases in plasma LDL-cholesterol and atherogenic indices in OC- treated rats. Treatment with OC did not result in significant attenuation in these parameters in OC+Mg- treated rats when compared with the controls. In conclusion, these results suggest that impaired glucose tolerance and dyslipidaemia associated with OC use may be prevented by increased dietary magnesium.
Keywords: Dietary magnesium, dyslipidaemia, glucose tolerance, oral contraceptive.
Résumé
Les études qui associent l’usage de l’oestrogen-progestogene contraceptif orale avec le glucose altéré et le métabolisme des lipides chez les femmes n’expliquaient pas l’influence possible du régime de magnésium. L’effet de l’OC, du glucose et du métabolisme des lipides demeure un problème de santé publique majeur, puisque plus de 100 millions de femmes utilisent l’OC dans le monde entier pour une période de temps prolongé. L’étude cherche donc à examiner si chez les rats femelles il y a ou pas intolérance du glucose et dyslipidemie associé à l’OC sont influencés par un état de régime en magnésium .les rats étaient divisés en groupes, de contrôle (CR), OC traitée, OC+Mg traité ( n=8 par groupe). Les rats du control et le OC traité étaient maintenus à un régime contrôlé, alors que les rats traités de OC+Mg étaient sous un régime en magnésium élevé. Les rats traités d’OC et ceux traitée d’OC+Mg recevaient aussi une combinaison de stéroïde OC (ethinyloestradiol et norgestrel, P.O). comparée au control, le traitement à l’OC conduit à une réduction importante en tolérance du glucose et du plasma HDL cholestérol et une augmentation importante dans le plasma LDL-cholesterol et les indices atherogeniques chez les rats traités d’OC. Le traitement avec l OC ne conduisait pas à une altération considérable en tolérance du glucose, le plasma HDL cholestérol, LDL-cholesterol et les indices atherogeniques chez les rats traités vde OC+Mg comparée à ceux du control. En conclusion, ces résultats suggèrent que la tolérance en glucose détérioré et la dyslipidemie associé à l’utilisation de l’OC peut être amélioré par un régime riche en magnésium.
Correspondence: Dr. L.A. Olatunji, Department of Physiology, College of Health Sciences, University of, PMB 1515, Ilorin, Nigeria. Email: tunjilaw04@yahoo.com.
Referències
Godsland IF, Crook D, Simpson R, Proudler T, Felton B, Lees B, Anyaoku V, Devenport M and Wynn V. The effects of different
formulations of oral contraceptive agents on lipid and Carbohydrate metabolism. N. Engl. Engl. J Med. 1990; 323: 1375-1381.
Gaspard UJ and Lefebvre PJ. Clinical aspects of the relationship between oral contraceptives abnormalities in carbohydrate
metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol 1990;163: 334-343.
Ginsberg HN. Treatment for patients with metabolic syndrome. Am J Cardiol 2003; 91: 29E-39E.
Assmann G, Schulte H, von Eckardstein A and Huang Y. High density lipoprotein cholesterol as a predictor of coronary
heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport
Atherosclerosis 1996; 124: S11-S20.
Criqui MH and Golomb BA. Epidemiological aspects of lipid abnormalities. Am J Med 1998; 105: 48S-57S.
Paolisso G and Barbagallo M.Hypertension,diabetes mellitus and insulin resistance: the role of intracellular magnesium. Am J
Hypertens 1997; 10: 346-355.
Rodrignez-Moran Mr and Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolism control
in type 2 Diabetic subjects: A randomized doubleblind controlled trial. Diabetes Care 2003; 26: 1147-1152.
Rosolova H, Mayer O and Reaven G. Effect of variations in plasma magnesium concentration on resistance to insulin-mediated
glucose disposal in nondiabetic subjects.J. Clin.Endocrin Metab 1997; 82: 3783-3785.
Huerta MG, Rolmmich JN, Kington ML,Bovbjerg VE, Weltman AL, Holmes VF, Patrie JT, Rogol AD and Nadler JL. Magnesium deficiency
is associated with insulin resistance in obese Children. Diabetes Care 2005; 28: 1175-1181
Reaven GM. Role of insulin resistance in human disease. Diabetes 1987; 37: 1595-1606.
Blum M, Kitai E, Arial Y, Schnierer and Bograd H. Oral contraceptive lowers magnesium. Harefuah. 1991; 121: 363-364
Hammed A, Mojeed T, Rauf S, Ashraf M, Jalil MA, Nasrullah M, Hussan A and Noreen R. Effect of oral and injectabel contraceptives on
serum calcium, magnesium and phosphorus in women. J Ayub Med Coll Abbottabad 2004; 13: 24-25.
Olatunji LA, Soladoye AO and Adegoke OA. Effect of combined oral contraceptive steroids on plasma lipid, lipid peroxidation and
nitric oxide biosynthesis in female rats. Nig Qt J Hosp Med 2004; 14: 224-226.
Burkman RT, Robinson JC, Kruszon-Moran D, Kimball AW, Kwiterovich P and Burford RG. Lipid and lipoprotein changes associated
with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 1988; 71: 33-38.
Arnold TS, Thye FW. The effects of an oral contraceptive on plasma growth hormone and glucose tolerance in two strains of rats. Am
J Clin Nutr 1977; 30: 381-387.
Olatunji LA and Soladoye AO. Increased magnesium intake prevents hyperlipidemia and insulin resistance and reduces lipid
peroxidation in fructose-fed rats. (doi:10.1016/j.pathophys. 2006.09.004)
Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without
use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
Suh S, Casazza GA, Horning MA, Miller BF and Brooks GA. Effects of oral contraceptives on glucose flux and substrate oxidation rates
during rest and exercise. Am J Physiol 2003; 94: 285-294.
Godsland IF, Walton C, Felton C, Provdler A, Petel A and Wynn F. Insulin resistance, secretion and metabolism in users of oral
contraceptives. J Clin Endocrinol Metab 1992;74;64-70
Haenni A, Ohrvall M and Lithell H. Atherogenic lipid fractions are related to ionized magnesium status. Am J Clin Nutr 1998; 67: 202-
Gueux E, Rayssigner Y, Piot MC and Alcindor L. Reduction of plasma lecithin cholesterol acyl-transferase activity by acute magnesium
deficiency in the rat. J Nutr 1984; 114: 1479-1483.
Mongenot N, Lesnik P, Ramirez-Gil JF, Hataf P, Diczfaluzy U, Chapman MJ and Lechat P. Effect of oxidation state of LDL on the
modulation of arterial vasomotor response in vitro. Atherosclerosis 1997; 133: 183-192.
O’Connel BJ and Genest J. High-density lipoproteins and endothelial function. Circulation 2001; 104: 1978-1983.
World Health Organization: Cardiovascular disease, and steroid hormone contraception report of WHO Scientific group WHO
Technical report series 1998; 877: 1-89.
Tanis BC, van den Bosch MAAJ, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, van der Graaf Y and Rosendaal FR. Oral
contraceptives the risk of myocardial infarction N Engl J Med 2001; 345; 1787-1793.